Biogen's Profit Guidance Rises Amid Leqembi Growth and MS Challenges

Leqembi, Biogen's Alzheimer’s drug developed with Eisai, is experiencing positive growth following an initially modest uptake, with U.S. sales increasing by 33% to $39 million and global sales climbing 66% to $67 million in the third quarter[1]. The company is focusing on simplified delivery methods, including a subcutaneous maintenance dose and an under-the-skin initiation formulation, with regulatory decisions anticipated next year and early 2026, respectively[1]. Despite challenges in its core business, Biogen has raised its earnings forecast, driven by the strong performance of new products like Leqembi[2]. The company is actively seeking to diversify its portfolio and enhance investor engagement by targeting peak annual sales from initiatives in Alzheimer’s, lupus, and autoimmune kidney conditions[2].